Lv11
40 积分 2024-08-08 加入
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
8小时前
待确认
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
3个月前
已完结
Clarifying intrinsic efficacy, partial agonism, and full agonism: moving beyond efficacy and affinity towards ligand-directed signalling. Comment on Br J Anaesth 2024; 132: 431–2
7个月前
已关闭
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
8个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
8个月前
已完结
Clinical development times for innovative drugs
10个月前
已完结
What matters most in commercial success: first-in-class or best-in-class?
10个月前
已完结
Chinese innovative drug R&D trends in 2024
10个月前
已完结
Different Development Strategies Affecting Japan’s Drug lag between Japan-Based and Foreign-Based Companies
11个月前
已完结
Investigating the origins of recent pharmaceutical innovation
11个月前
已完结
皖公网安备34019202002308
